Spero Therapeutics (SPRO) Stock Rating Lowered by Zacks Investment Research

Spero Therapeutics (NASDAQ:SPRO) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Wednesday.

According to Zacks, “Spero Therapeutics Inc. is a multi-asset, clinical-stage biopharmaceutical company. It focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections. Spero Therapeutics Inc. is based in CAMBRIDGE, United States. “

A number of other analysts have also recently commented on the company. Bank of America started coverage on Spero Therapeutics in a research report on Monday, November 27th. They set a “neutral” rating for the company. Oppenheimer started coverage on Spero Therapeutics in a research report on Monday, November 27th. They set a “buy” rating and a $30.00 price objective for the company. Stifel Nicolaus started coverage on Spero Therapeutics in a research report on Monday, November 27th. They set a “buy” rating and a $26.00 price objective for the company. Cowen started coverage on Spero Therapeutics in a research report on Monday, November 27th. They set an “outperform” rating for the company. Finally, ValuEngine upgraded Spero Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $24.25.

Spero Therapeutics (NASDAQ SPRO) traded down $0.36 during trading on Wednesday, reaching $11.20. The company had a trading volume of 15,600 shares, compared to its average volume of 24,633. Spero Therapeutics has a 1 year low of $9.75 and a 1 year high of $15.40.

Spero Therapeutics (NASDAQ:SPRO) last posted its quarterly earnings data on Thursday, December 14th. The company reported ($36.02) EPS for the quarter, missing analysts’ consensus estimates of ($2.43) by ($33.59). The company had revenue of $0.60 million during the quarter, compared to analysts’ expectations of $0.20 million. analysts expect that Spero Therapeutics will post -8.52 earnings per share for the current year.

A number of institutional investors have recently bought and sold shares of the stock. Rock Springs Capital Management LP purchased a new stake in Spero Therapeutics during the 4th quarter worth about $6,169,000. VHCP Management II LLC purchased a new stake in Spero Therapeutics in the 4th quarter valued at about $5,706,000. AWM Investment Company Inc. purchased a new stake in Spero Therapeutics in the 4th quarter valued at about $4,112,000. Artal Group S.A. purchased a new stake in Spero Therapeutics in the 4th quarter valued at about $4,113,000. Finally, BlackRock Inc. purchased a new stake in Spero Therapeutics in the 4th quarter valued at about $2,830,000. Hedge funds and other institutional investors own 9.85% of the company’s stock.

WARNING: This report was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another domain, it was illegally copied and reposted in violation of US & international trademark & copyright legislation. The legal version of this report can be accessed at https://www.americanbankingnews.com/2018/02/14/spero-therapeutics-spro-stock-rating-lowered-by-zacks-investment-research.html.

About Spero Therapeutics

Spero Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing novel treatments for MDR bacterial infections. The Company is developing a portfolio of novel product candidates, including SPR994, Potentiator Platform (SPR741 and SPR206), and SPR720.

Get a free copy of the Zacks research report on Spero Therapeutics (SPRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Spero Therapeutics (NASDAQ:SPRO)

Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply